184 related articles for article (PubMed ID: 24820112)
1. A new grading system for ototoxicity in adults.
Theunissen EA; Dreschler WA; Latenstein MN; Rasch CR; van der Baan S; de Boer JP; Balm AJ; Zuur CL
Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Long-term hearing loss after chemoradiation in patients with head and neck cancer.
Theunissen EA; Zuur CL; Bosma SC; Lopez-Yurda M; Hauptmann M; van der Baan S; de Boer JP; van der Molen L; Rasch CR; Dreschler WA; Balm AJ
Laryngoscope; 2014 Dec; 124(12):2720-5. PubMed ID: 24964759
[TBL] [Abstract][Full Text] [Related]
4. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
Zuur CL; Simis YJ; Lamers EA; Hart AA; Dreschler WA; Balm AJ; Rasch CR
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):490-6. PubMed ID: 19135315
[TBL] [Abstract][Full Text] [Related]
6. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
[TBL] [Abstract][Full Text] [Related]
9. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
10. Clinically accurate assessment and grading of ototoxicity.
Chang KW
Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
[TBL] [Abstract][Full Text] [Related]
11. Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW; Chinosornvatana N
J Clin Oncol; 2010 Apr; 28(10):1788-95. PubMed ID: 20194861
[TBL] [Abstract][Full Text] [Related]
12. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population.
Chan SL; Ng LS; Goh X; Siow CH; Goh HL; Goh BC; Cheo T; Loh KS; Brunham LR
Head Neck; 2018 Jul; 40(7):1425-1433. PubMed ID: 29451951
[TBL] [Abstract][Full Text] [Related]
13. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
14. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
15. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
16. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
Mahdavi SR; Rezaeyan A; Nikoofar A; Bakhshandeh M; Farahani S; Cheraghi S
J Cancer Res Ther; 2020; 16(3):539-545. PubMed ID: 32719264
[TBL] [Abstract][Full Text] [Related]
17. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
[TBL] [Abstract][Full Text] [Related]
18. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
Colevas AD; Lira RR; Colevas EA; Lavori PW; Chan C; Shultz DB; Chang KW
Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
[TBL] [Abstract][Full Text] [Related]
19. Predicting the degree of hearing loss using click auditory brainstem response in babies referred from newborn hearing screening.
Baldwin M; Watkin P
Ear Hear; 2013; 34(3):361-9. PubMed ID: 23340456
[TBL] [Abstract][Full Text] [Related]
20. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria.
Beahan N; Kei J; Driscoll C; Charles B; Khan A
Ear Hear; 2012; 33(1):104-11. PubMed ID: 21760512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
